197 related articles for article (PubMed ID: 25220739)
21. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
Grimmsmann T; Himmel W
Eur J Clin Pharmacol; 2021 Jan; 77(1):107-115. PubMed ID: 32803292
[TBL] [Abstract][Full Text] [Related]
22. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
Braun S; Russo L; Zeidler J; Linder R; Hodgkins P
Clin Ther; 2013 May; 35(5):673-85. PubMed ID: 23587606
[TBL] [Abstract][Full Text] [Related]
23. Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
Wang LJ; Shyu YC; Yuan SS; Yang CJ; Yang KC; Lee TL; Lee SY
J Psychiatr Res; 2016 Jan; 72():6-14. PubMed ID: 26519764
[TBL] [Abstract][Full Text] [Related]
24. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
26. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
27. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study.
Norum J; Olsen AI; Nohr FI; Heyd A; Totth A
Glob J Health Sci; 2014 Apr; 6(4):155-62. PubMed ID: 24999151
[TBL] [Abstract][Full Text] [Related]
28. Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study.
Munasur-Naidoo AP; Truter I
Int J Clin Pharm; 2019 Aug; 41(4):859-863. PubMed ID: 31313002
[TBL] [Abstract][Full Text] [Related]
29. Patterns of long-term ADHD medication use in Australian children.
Efron D; Mulraney M; Sciberras E; Hiscock H; Hearps S; Coghill D
Arch Dis Child; 2020 Jun; 105(6):593-597. PubMed ID: 31937570
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics.
Gumy C; Huissoud T; Dubois-Arber F
J Atten Disord; 2010 Nov; 14(3):267-72. PubMed ID: 20484708
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder.
Chen CY; Yeh HH; Chen KH; Chang IS; Wu EC; Lin KM
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):265-73. PubMed ID: 21663429
[TBL] [Abstract][Full Text] [Related]
32. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
Stuhec M; Locatelli I
Int J Clin Pharm; 2018 Apr; 40(2):341-344. PubMed ID: 29468526
[TBL] [Abstract][Full Text] [Related]
33. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
Song I; Shin JY
Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
[TBL] [Abstract][Full Text] [Related]
34. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective.
Pottegård A; Bjerregaard BK; Glintborg D; Hallas J; Moreno SI
Eur J Clin Pharmacol; 2012 Oct; 68(10):1443-50. PubMed ID: 22434389
[TBL] [Abstract][Full Text] [Related]
35. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
36. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
Sørensen AMS; Wesselhöeft R; Andersen JH; Reutfors J; Cesta CE; Furu K; Hartz I; Rasmussen L
Eur Child Adolesc Psychiatry; 2023 Oct; 32(10):2049-2056. PubMed ID: 35831669
[TBL] [Abstract][Full Text] [Related]
37. [Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002].
Huissoud T; Jeannin A; Dubois-Arber F
Rev Epidemiol Sante Publique; 2007 Oct; 55(5):357-63. PubMed ID: 17889474
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, incidence and persistence of ADHD drug use in Japan.
Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J
Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548
[No Abstract] [Full Text] [Related]
40. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
Janols LO; Liliemark J; Klintberg K; von Knorring AL
Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
